Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.72 |
| ▸ | CDH1 | P12830 | 1/20 | 0.72 |
| ▸ | APC | P25054 | 1/20 | 0.72 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.72 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.72 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.55 |
| ▸ | BAD | Q92934 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17184420 | 0.90 | CDH1 (0.68) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL23416437 | 0.86 | RPS6KB2 (0.64) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL17184408 | 0.86 | CDH1 (0.70) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL18995965 | 0.86 | KDM4E (0.57) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL17184412 | 0.86 | CDH1 (0.57) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL15665863 | 0.85 | HPGD (0.93) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL15666427 | 0.85 | HPGD (0.93) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL1258992 | 0.85 | ALDH1A1 (0.76) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL6291531 | 0.85 | ALDH1A1 (1.00) | ALDH1A1GAARAB9AKDM4EHPGD | |
| SCHEMBL30555665 | 0.85 | ALDH1A1 (1.00) | ALDH1A1GAARAB9AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310424-A1 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-10-05 | — | — | US | disclosed |
| US-20230310424-A1 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-10-05 | — | — | US | disclosed |
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-02-09 | — | — | US | disclosed |
| WO-2022109311-A1 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2021102370-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-05-27 | — | — | WO | disclosed |
| US-10144742-B2 | Quinoxaline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3131881-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-20150141422-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-05-21 | — | — | US | disclosed |
| US-20150141422-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-05-21 | — | — | US | disclosed |
| US-20150141422-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX, LLC | 2015-05-21 | — | — | US | disclosed |
| US-20140128392-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128392-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128392-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2014-05-08 | — | — | US | disclosed |
| US-7189724-B2 | Quinoxaline derivatives having antiviral activity | VALEANT RESEARCH AND DEVELOPMENT (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189724-B2 | Quinoxaline derivatives having antiviral activity | VALEANT RESEARCH AND DEVELOPMENT (US) | 2007-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310424-A1 | METHODS AND MATERIALS FOR INCREASING NICOTINAMIDE PHOSPHORIBOSYL TRANSFERASE ACTIVITY | NAMPT, NNMT, NAPRT | ALDH1A1 1726/4885GAA 235/4885RAB9A 1946/4885 |
| US-10144742-B2 | Quinoxaline compounds and uses thereof | NAMPT, NQO2, NNMT | ALDH1A1 1374/4885GAA 3128/4885RAB9A 787/4885 |
| US-20230041576-A1 | METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY | NFKBIA, IKBKB, NFKB2 | ALDH1A1 4286/4885GAA 403/4885RAB9A 2742/4885 |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | ALDH1A1 1374/4885GAA 3128/4885RAB9A 787/4885 |
| US-20150141422-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ALDH1A1 3714/4885GAA 306/4885RAB9A 983/4885 |
| US-20140128392-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | ALDH1A1 3255/4885GAA 423/4885RAB9A 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.